Research
Hormonal
Subcutaneous semaglutide (2.4 mg once weekly) produces clinically significant weight loss (mean -14.9% body weight) compared to placebo when combined with lifestyle interventions.
If you have obesity, adding weekly semaglutide (2.4 mg) to your existing diet and exercise plan can help you lose significantly more weight (around 15%) than diet and exercise alone. Start with the lowest dose and increase it slowly every few weeks to avoid stomach issues.
StrongSupportsVERY_HIGH confidence
At week 68, in the semaglutide group, the mean change in body weight was −14.9% compared to −2.4% in the placebo group (p < 0.001).
Why this rating
Based on multiple large-scale Phase 3 randomized controlled trials (STEP 1-4) with >5000 participants.
Source
Clinical review of subcutaneous semaglutide for obesity
Anna C. Phillips et al. · Journal of Clinical Pharmacy and Therapeutics · 2021
DOI 10.1111/jcpt.13574
narrative_review · n=5000Cited 46×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →